• Home
  • Access
JAPANESE
  • Technologies
  • Products
  • About PSS
  • Investor Relations
  • FAQ / Contact

Home > Investor Relations > Management Policy > Business guideline

Investor Relations

Business guideline

Precision System Science Co., Ltd. (PSS) sets business guidelines for execution of business based on the management policy in the early phase of each fiscal year. The business guidelines thus determined are those used as strategic measures to counter currently foreseeable PSS's business risks (risks possibly affecting operating results, stock price and financial situations and others of the PSS group).

Business guidelines for FY 26 (June/2011)

1. Establishment of growth models by development of new break-through products in the bio-industry through integrating PSS's original technologies:

(1)LuBEA® (Line up Beads Assay) system

What PSS aims at is to provide automated systems with overwhelmingly higher in cost performance to the world in the in-vitro diagnosis (IVD) market mainly related to medicine. The LuBEA® system, which is under research and development for the purpose above, was selected recently as a contracted research project promoted by NEDO continuously, and the members in the project are now under development aimed at practical application of a "rapid simple system for quantitative determination of particular food allergens".

(2)GeneLEAD®

PSS is also engaged in development of a compact size general-purpose system for gene analysis, GeneLEAD®, based on the same concept. The system is also aimed at application to the test of swine-origin influenza concerned about epidemic, and the development is in progress rapidly and intensively.

2. Increase of the earning capacity of existing business: improvement of return on sales

Automated DNA extraction system, major source of profit, are expanding their sales mainly with the version upgrade products of Roche and Qiagen groups. These apparatuses, which are compatible with pretreatment (extraction of viral RNAs) of viral tests, are finding increasing worldwide demand and contributed significantly to increased sales and profit, even in recession of world economy and even with appreciation of the yen. Similarly in this fiscal year too, the PSS's technology and products will be accepted and used in many facilities.

To cope with the appreciation of the yen, PSS has adjusted the exchange risk with OEM customers and reduced cost by procurement taking advantage of high exchange rate. Furthermore, PSS invested in NPS, a sub-contracting manufacturer, for more efficient production management.

3. Reduction of sales and administrative expense: for profitability of final profit or loss

PSS has maintained stable expense level despite the rapid increase of net sales seen in FY25. All members in the PSS group are required to continue their joint effort to reduce expenses in this fiscal year too.

  • Home
  • Technologies
  • Products
  • About PSS
  • Investor Relations
  • FAQ / Contact
TOP